Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia

被引：7
|
作者：
Wei, Hui [1 ,2 ,3 ,4 ]
Zhou, Chunlin [3 ,4 ]
Lin, Dong [3 ,4 ]
Liu, Bingcheng [3 ,4 ]
Li, Yan [3 ,4 ]
Zhao, Xingli [3 ,4 ]
Wei, Shuning [3 ,4 ]
Gong, Benfa [3 ,4 ]
Liu, Kaiqi [3 ,4 ]
Gong, Xiaoyuan [3 ,4 ]
Liu, Yuntao [3 ,4 ]
Zhang, Guangji [3 ,4 ]
Chen, Jiayuan [1 ]
Zhang, Junping [3 ,4 ]
Jin, Jingjing [3 ,4 ]
Qiu, Shaowei [3 ,4 ]
Gu, Runxia [3 ,4 ]
Wang, Ying [2 ,3 ,4 ]
Mi, Yingchan [1 ,2 ,3 ,4 ]
Wang, Jianxiang [1 ,2 ,3 ,4 ]
机构：
[1] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci, Inst Hematol, Natl Clin Res Ctr Blood Dis, Tianjin, Peoples R China
[3] Chinese Acad Med Sci, Inst Hematol, Leukemia Ctr, Tianjin, Peoples R China
[4] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 05期
基金：
中国国家自然科学基金;
关键词：
RANDOMIZED-TRIAL; ADULTS; DAUNORUBICIN; AML;
D O I：
10.3324/haematol.2020.267526
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1491 / 1495
页数：5
相关论文
共 50 条
  • [41] Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502
    Attar, Eyal C.
    Johnson, Jeffrey L.
    Amrein, Philip C.
    Lozanski, Gerard
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Kolitz, Jonathan E.
    Powell, Bayard L.
    Voorhees, Peter
    Wang, Eunice S.
    Blum, William
    Stone, Richard M.
    Marcucci, Guido
    Bloomfield, Clara D.
    Moser, Barry
    Larson, Richard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (07) : 923 - 929
  • [42] Comparison of Frontline Induction Therapy Using Idarubicin in Combination with High-Dose (HDAC3) Versus Intermediate-Dose Cytarabine (IDAC3) in Adult Acute Myeloid Leukemia
    Tiong, Ing Soo S.
    Fielding, Katherine
    Fong, Chun Y.
    Bortz, Hadley
    Avery, Sharon
    Grigg, Andrew P.
    Wei, Andrew
    BLOOD, 2017, 130
  • [43] The Intermediate Dose Verse Conventional Dose Cytarabine in Induction Therapy in Adult Acute Myeloid Leukemia: A Phase III Randomized Controlled Trial
    Wei, Hui
    Wang, Ying
    Lin, Dong
    Zhou, Chunlin
    Liu, Bingcheng
    Qiu, Shaowei
    Gong, Benfa
    Liu, Kaiqi
    Zhang, Guangji
    Wei, Shuning
    Gong, Xiaoyuan
    Liu, Yuntao
    Li, Yan
    Mi, Yingchang
    Wang, Jianxiang
    BLOOD, 2017, 130
  • [44] Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia – results of a phase-II trial
    F. Schneller
    M. Schuler
    K. Schumacher
    J. Thaler
    C. Peschel
    C. Huber
    W. Aulitzky
    Annals of Hematology, 1998, 77 : 225 - 229
  • [45] Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia - results of a phase-II trial
    Schneller, F
    Schuler, M
    Schumacher, K
    Thaler, J
    Peschel, C
    Huber, C
    Aulitzky, W
    ANNALS OF HEMATOLOGY, 1998, 77 (05) : 225 - 229
  • [46] Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group
    Kolonen, Aarne
    Sinisalo, Marjatta
    Huhtala, Heini
    Rimpilainen, Johanna
    Rintala, Hannele
    Sankelo, Marja
    Koivunen, Elli
    Silvennoinen, Raija
    Raty, Riikka
    Ruutu, Tapani
    Volin, Liisa
    Porkka, Kimmo
    Jantunen, Esa
    Nousiainen, Tapio
    Kuittinen, Taru
    Penttila, Karri
    Pyorala, Marja
    Saily, Marjaana
    Koistinen, Pirjo
    Kauppila, Marjut
    Itala-Remes, Maija
    Ollikainen, Hanna
    Rauhala, Auvo
    Kairisto, Veli
    Pelliniemi, Tarja-Terttu
    Elonen, Erkki
    Group, Finnish Leukemia
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (03) : 257 - 270
  • [47] High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia
    Chen, SH
    Liang, DC
    Liu, HC
    AMERICAN JOURNAL OF HEMATOLOGY, 1998, 58 (01) : 20 - 23
  • [48] Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine
    Wiedower, Eric
    Jamy, Omer
    Martin, Michael G.
    ANTICANCER RESEARCH, 2015, 35 (11) : 6287 - 6290
  • [49] Salvage chemotherapy with mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC) in refractory or relapsed acute leukemia in adults.
    Jang, JH
    Lee, ST
    Hahn, JS
    Ko, YW
    Min, YH
    BLOOD, 2001, 98 (11) : 213B - 213B
  • [50] Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia
    Lee, JH
    Choi, SJ
    Lee, JH
    Lee, YS
    Seol, M
    Ryu, SG
    Jang, S
    Park, CJ
    Chi, HS
    Lee, JS
    Kim, WK
    Lee, KH
    LEUKEMIA RESEARCH, 2006, 30 (02) : 204 - 210
12345